Related Experiment Video
Updated: Apr 26, 2026

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
Layer-by-layer engineered outer membrane vesicles enable oral upadacitinib delivery for inflammation control and
Ruoxue Dai1, Shuang Che1, Ying Shi1,2
1The Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, Department of Radiology and Nuclear Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Abstract:
Ulcerative colitis (UC) is characterized by intertwined defects in the epithelial barrier, microbiota composition, and immune signaling, which collectively sustain inflammation and drive fibrosis. Here, we report a multifunctional oral nanoplatform OMV-LbL@Upa (OUL), comprising probiotic-derived outer membrane vesicles (OMVs) encapsulating the JAK-STAT inhibitor upadacitinib (Upa), further functionalized with a trans-cinnamic acid/chitosan-based layer-by-layer (LbL) coating. The LbL architecture significantly enhanced gastric stability and intestinal retention, enabling colon-targeted release while preserving OMV bioactivity. In both acute and chronic UC models, OUL significantly improved disease activity, restored tight junction proteins, corrected intestinal permeability, rebalanced gut microbiota, and reprogrammed macrophage polarization. Mechanistically, OUL suppressed JAK-STAT signaling pathways, culminating in attenuated collagen deposition and the downregulation of pro-fibrotic markers (α-SMA and vimentin). With no overt systemic toxicity observed, this orally administered nanoplatform integrates microbiota/epithelial restoration with targeted JAK1 inhibition to achieve anti-inflammatory and anti-fibrotic benefits, offering a clinically promising strategy for the management of UC.
More Related Videos
Related Concept Videos
Oral Drug Delivery Systems: Delayed-Release Systems
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Oral Drug Delivery Systems: Introduction

